Investing.com - RBC Capital has raised its price target on Compass Pathways (NASDAQ:CMPS) to $21.00 from $16.00 while maintaining an Outperform rating on the stock. Currently trading at $7.13, CMPS ...

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...

Investing.com - RBC Capital raised its price target on Compass Pathways (NASDAQ:CMPS) to $22 from $21 while maintaining an Outperform rating. The stock, currently trading at $7.63, has shown ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

The big shareholder groups in COMPASS Pathways plc (NASDAQ:CMPS) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders ...

The company reported that in the 25 mg arm of its trial, there was a statistically significant reduction in symptom severity for treatment-resistant depression. In COMP006, two doses of COMP360 25 mg ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...